AJP Explains Publishing ‘Mystery’

Have you ever wondered about the decision-making process used to determine which studies are published by the American Journal of Psychiatry (AJP)?

At APA's 2010 annual meeting in New Orleans, you'll get some insight into the answer in a symposium led by AJP Editor Robert Freedman, M.D. He will use the June issue to explain how submission decisions are made as he highlights important research reported in that issue. He will be joined by some of the authors from studies published in that issue.

The symposium, titled “New Studies to Appear in the June American Journal of Psychiatry—Presentations by the Authors and Editors,” will be held on Monday, May 24, at 2 p.m. in room 225/226 at the Morial Convention Center.

Here are some of the papers that at press time were scheduled to appear in AJP's June issue: “A Dissociative Subtype of PTSD: Clinical and Neurobiological Evidence” (lead author: David Spiegel, M.D.); “International Consensus Study of Antipsychotic Dosing” (lead author: David Gardner, M.D.); “A Double-Blind, Placebo-Controlled Trial That Combines Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence” (lead author: Helen Pettinati, Ph.D.); and “Time-to-Attainment of Recovery From Borderline Personality Disorder and Its Stability: A 10-Year Prospective Follow-Up Study” (lead author: Mary Zanarini, Ed.D.).